These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28383817)

  • 1. CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy.
    Zwaenepoel K; Jacobs J; De Meulenaere A; Silence K; Smits E; Siozopoulou V; Hauben E; Rolfo C; Rottey S; Pauwels P
    Histopathology; 2017 Sep; 71(3):357-365. PubMed ID: 28383817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related.
    Bai Y; Guo T; Huang X; Wu Q; Niu D; Ji X; Feng Q; Li Z; Kakudo K
    Virchows Arch; 2018 May; 472(5):779-787. PubMed ID: 29651624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive screening for PD-L1 expression in thyroid cancer.
    Ahn S; Kim TH; Kim SW; Ki CS; Jang HW; Kim JS; Kim JH; Choe JH; Shin JH; Hahn SY; Oh YL; Chung JH
    Endocr Relat Cancer; 2017 Feb; 24(2):97-106. PubMed ID: 28093480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
    Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
    Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.
    Bastman JJ; Serracino HS; Zhu Y; Koenig MR; Mateescu V; Sams SB; Davies KD; Raeburn CD; McIntyre RC; Haugen BR; French JD
    J Clin Endocrinol Metab; 2016 Jul; 101(7):2863-73. PubMed ID: 27045886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry.
    Ahn J; Jin M; Song E; Ryu YM; Song DE; Kim SY; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
    Thyroid; 2021 Jan; 31(1):61-67. PubMed ID: 32611231
    [No Abstract]   [Full Text] [Related]  

  • 7. PD-L1 expression in extrahepatic cholangiocarcinoma.
    Walter D; Herrmann E; Schnitzbauer AA; Zeuzem S; Hansmann ML; Peveling-Oberhag J; Hartmann S
    Histopathology; 2017 Sep; 71(3):383-392. PubMed ID: 28419539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma.
    Girolami I; Pantanowitz L; Mete O; Brunelli M; Marletta S; Colato C; Trimboli P; Crescenzi A; Bongiovanni M; Barbareschi M; Eccher A
    Endocr Pathol; 2020 Sep; 31(3):291-300. PubMed ID: 32468210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 Expression and Its Modulating Factors in Anaplastic Thyroid Carcinoma: A Multi-institutional Study.
    Agarwal S; Jung CK; Gaddam P; Hirokawa M; Higashiyama T; Hang JF; Lai WA; Keelawat S; Liu Z; Na HY; Park SY; Fukuoka J; Satoh S; Mussazhanova Z; Nakashima M; Kakudo K; Bychkov A
    Am J Surg Pathol; 2024 Oct; 48(10):1233-1244. PubMed ID: 39004795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer.
    Cantara S; Bertelli E; Occhini R; Regoli M; Brilli L; Pacini F; Castagna MG; Toti P
    Endocrine; 2019 Apr; 64(1):122-129. PubMed ID: 30762153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
    Garber ST; Hashimoto Y; Weathers SP; Xiu J; Gatalica Z; Verhaak RG; Zhou S; Fuller GN; Khasraw M; de Groot J; Reddy SK; Spetzler D; Heimberger AB
    Neuro Oncol; 2016 Oct; 18(10):1357-66. PubMed ID: 27370400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.
    Adam P; Kircher S; Sbiera I; Koehler VF; Berg E; Knösel T; Sandner B; Fenske WK; Bläker H; Smaxwil C; Zielke A; Sipos B; Allelein S; Schott M; Dierks C; Spitzweg C; Fassnacht M; Kroiss M
    Front Endocrinol (Lausanne); 2021; 12():712107. PubMed ID: 34475850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
    Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
    Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 and B7-H3 are Effective Prognostic Factors and Potential Therapeutic Targets for High-Risk Thyroid Cancer.
    Zhu X; Hu C; Zhang Z; Zhu Y; Liu W; Zheng B; Feng X; Lu H
    Endocr Pathol; 2024 Sep; 35(3):230-244. PubMed ID: 39102163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study.
    Fadia M; Fookeerah P; Ali S; Shadbolt B; Greenaway T; Perampalam S
    Pathology; 2020 Apr; 52(3):318-322. PubMed ID: 32107082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line.
    Hegedűs L; Rittler D; Garay T; Stockhammer P; Kovács I; Döme B; Theurer S; Hager T; Herold T; Kalbourtzis S; Bankfalvi A; Schmid KW; Führer D; Aigner C; Hegedűs B
    Pathol Oncol Res; 2020 Oct; 26(4):2523-2535. PubMed ID: 32591993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROGRAMMED CELL DEATH-LIGAND 1 OVEREXPRESSION IN THYROID CANCER.
    Zhang GQ; Wei WJ; Song HJ; Sun ZK; Shen CT; Zhang XY; Chen XY; Qiu ZL; Luo QY
    Endocr Pract; 2019 Mar; 25(3):279-286. PubMed ID: 30913016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel histological examination with dynamic three-dimensional reconstruction from multiple immunohistochemically stained sections of a PD-L1-positive colon cancer.
    Korehisa S; Ikeda T; Okano S; Saeki H; Oki E; Oda Y; Hashizume M; Maehara Y
    Histopathology; 2018 Mar; 72(4):697-703. PubMed ID: 28940664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer.
    Gunda V; Gigliotti B; Ndishabandi D; Ashry T; McCarthy M; Zhou Z; Amin S; Freeman GJ; Alessandrini A; Parangi S
    Br J Cancer; 2018 Nov; 119(10):1223-1232. PubMed ID: 30327563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.